Karimpour-razkenari, 31 patient melatonin ICU study: 39% lower mortality [p=0.37], 43% shorter ventilation [p=0.13], and 2% lower ICU admission [p=0.85] https://c19p.org/karimpourrazkenari
copied to clipboard
Melatonin as adjunctive therapy in patients admitted to the Covid-19
et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103492
Retrospective 31 ICU patients, 12 treated with melatonin, showing lower mortality with treatment, without statistical significance. Melatonin 15mg daily.
|
risk of death, 39.0% lower, HR 0.61, p = 0.37, treatment 5 of 12 (41.7%), control 13 of 19 (68.4%), NNT 3.7, Kaplan–Meier.
|
|
ventilation time, 42.9% lower, relative time 0.57, p = 0.13, treatment 12, control 19.
|
|
ICU time, 1.9% lower, relative time 0.98, p = 0.85, treatment 12, control 19.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Karimpour-razkenari et al., 3/10/2022, retrospective, Iran, Middle East, peer-reviewed, 6 authors, study period 13 March, 2020 - 30 May, 2020.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.